Is CRIS a buy? - Seeking Alpha

Quote & Headlines Market Currents StockTalk

Today 5d 1m 3m 1y 5y 10y

52wk high:

52wk low:

EPS:

PE:

Div Rate:

Yield:

Market Cap:

Volume:

1,008 people get CRIS articles and Market Currents by email alert.

Get email alerts on CRIS »

HEADLINES:

Curis Announces Presentation of CUDC-427 and Erivedge(R) Clinical Results at ASCO Annual Meeting

GlobeNewswire (Thu, 7:00AM)
Curis Announces Approval of Erivedge(R) in Australia

GlobeNewswire (May 10, 2013)
Curis Management Discusses Q1 2013 Results - Earnings Call Transcript
Tue, Apr 30
Curis Reports First Quarter 2013 Financial Results

GlobeNewswire (Apr 30, 2013)
Curis Announces Erivedge(R) Receives Positive CHMP Opinion for Conditional Approval in European Union

GlobeNewswire (Apr 26, 2013)
Curis to Present at the Needham 12th Annual Healthcare Conference

GlobeNewswire (Apr 24, 2013)
Curis to Release First Quarter 2013 Financial Results and Hold Conference Call on April 30, 2013

GlobeNewswire (Apr 23, 2013)
Following The Crashing Biotechs - 4 Stocks Ready For Spring
Craig Keolanui • Mon, Apr 8 • 6 Comments
Curis to Present at the BioCentury Future Leaders in the Biotech Industry Conference

GlobeNewswire (Mar 29, 2013)
Curis Announces Appointment of Kenneth Pienta, M.D. to Board of Directors

GlobeNewswire (Mar 11, 2013)
Curis to Present at the Roth Capital Partners 25th Annual Growth Stock Conference

GlobeNewswire (Mar 11, 2013)
Curis' CEO Presents at Citi 2013 Global Healthcare Conference (Transcript)
Mon, Feb 25
Curis to Present at the Cowen and Company 33rd Annual Health Care Conference

GlobeNewswire (Feb 25, 2013)
Curis Management Discusses Q4 2012 Results - Earnings Call Transcript
Wed, Feb 20
Curis Reports Fourth Quarter and Year-End 2012 Financial Results

GlobeNewswire (Feb 20, 2013)
Curis Appoints Ali Fattaey, Ph.D. as President and Chief Operating Officer

GlobeNewswire (Feb 19, 2013)
Curis to Present at Upcoming Investor Conferences

GlobeNewswire (Feb 15, 2013)
Curis to Release Fourth Quarter and Year End 2012 Financial Results and Hold Conference Call on February 20, 2013

GlobeNewswire (Feb 13, 2013)
Curis Announces Dosing of First Patient in Phase I Clinical Trial of Dual PI3 Kinase and HDAC Inhibitor CUDC-907

GlobeNewswire (Jan 24, 2013)
Biotech Portfolio Update: 2012 Summary And 2013 Outlook
Ohad Hammer • Mon, Dec 24, 2012 • 11 Comments

To learn more about Seeking Alpha Pro, click here.

Curis: 4 Reasons To Consider This $4 Stock
Derek Chipman • Mon, Oct 22, 2012 • 9 Comments
Curis: A Stock Fueled By Sonic Hedgehog
Eric Wick • Mon, Oct 22, 2012 • 23 Comments
Curis: New Data Shows Efficacy In Advanced Pancreatic Cancer
Missouri Heights Alpha Fund • Tue, Jun 19, 2012 • 5 Comments
Curis Operable BCC Human Data: Early Results And Further Commentary
Missouri Heights Alpha Fund • Sun, Apr 15, 2012 • 4 Comments
AACR Annual Oncology Meeting: A Look Into Various Abstracts
Missouri Heights Alpha Fund • Tue, Mar 27, 2012 • 4 Comments
Curis: Potential Blockbuster Application In Pancreatic Cancer
Missouri Heights Alpha Fund • Tue, Mar 20, 2012 • 12 Comments
Curis Earns $8 Million Milestone As NDA Accepted By FDA
M. E. Garza • Thu, Nov 10, 2011 • 2 Comments
Curis: Next Week's Data Release Could Bring Volatility to Shares
Alex Shadunsky • Fri, Jun 17, 2011
Curis' 'Hedgehog' Inhibitor to Offer Hope for Basal Cell Carcinoma Sufferers
Chemistfrog • Mon, Feb 28, 2011 • 8 Comments
Curis' Cancer Therapy Arouses Curiosity
SoundView Technology Group • Sun, Sep 6, 2009 • 1 Comment

Following The Crashing Biotechs - 4 Stocks Ready For Spring
Craig Keolanui • Mon, Apr 8 • 6 Comments
Biotech Portfolio Update: 2012 Summary And 2013 Outlook
Ohad Hammer • Mon, Dec 24, 2012 • 11 Comments
2 Biotech Firms With Significant Upside In The Wake Of Recent Developments
Matt Schilling • Mon, Dec 10, 2012 • 9 Comments
Formation Of A New Expert Group Moves Pluristem Into The Expansive Hematology Field
Sharon di Stefano • Wed, Dec 5, 2012 • 39 Comments
Casey Analyst Forecasts Explosive Biotech Growth
Life Sciences Report • Thu, Oct 11, 2012
5 Pharmaceutical Companies With EMA Catalysts During The Next 3-12 Months
Markus Aarnio • Fri, Aug 31, 2012 • 32 Comments
Winners Of ASCO 2012
Ohad Hammer • Mon, Jun 11, 2012 • 12 Comments
Analyzing Noteworthy Insider Trades Last Week In Regeneron, Covidien, And Other Healthcare Stocks
GuruFundPicks • Mon, May 7, 2012
Threshold Pharmaceuticals: TH-302 Phase IIb Clinical Results In First-Line Pancreatic Cancer
LifeSci Advisors • Fri, Apr 27, 2012 • 22 Comments
Analyzing Thursday And Friday's Noteworthy Insider Trades
GuruFundPicks • Mon, Apr 23, 2012
Top Small-Cap Biotech Stocks Being Accumulated By Legendary Fund Managers
GuruFundPicks • Tue, Apr 17, 2012 • 6 Comments
Analyzing Thursday's Noteworthy Insider Trades In The Healthcare Sector
GuruFundPicks • Fri, Mar 30, 2012 • 2 Comments
Small-Cap Biotech Stocks Being Accumulated By The World's Largest Money Managers
GuruFundPicks • Thu, Mar 29, 2012 • 10 Comments
Keryx: A Biotech For Aggressive Investors
Mel Daris • Wed, Mar 28, 2012 • 2 Comments
MELA Sciences: A Hidden Gem That Could Bring A Stock Price Double This Year
Scott Matusow • Tue, Mar 6, 2012 • 29 Comments
4 Biotech Stocks Trading At A Steep Discount To Target Price
Kapitall • Sun, Mar 4, 2012 • 5 Comments
The 9 Biotechs With The Highest Growth Expectations
Kinetic Investments • Fri, Feb 3, 2012 • 15 Comments
Analysis Of Monday And Tuesday's Noteworthy Institutional 5% Ownership Filings
GuruFundPicks • Tue, Jan 31, 2012
2011 Review And Outlook For Biotechnology In 2012
Michael Becker • Wed, Jan 25, 2012 • 2 Comments
'Top of The Class' Biotechs For 2012
Chemistfrog • Wed, Jan 11, 2012 • 6 Comments

Curis Management Discusses Q1 2013 Results - Earnings Call Transcript
Tue, Apr 30
Curis' CEO Presents at Citi 2013 Global Healthcare Conference (Transcript)
Mon, Feb 25
Curis Management Discusses Q4 2012 Results - Earnings Call Transcript
Wed, Feb 20
Curis' CEO Discusses Q3 2012 Results - Earnings Call Transcript
Tue, Nov 6, 2012
Curis Management Discusses Q2 2012 Results - Earnings Call Transcript
Thu, Aug 2, 2012
Curis, Inc. Q1 2010 Earnings Call Transcript
Fri, May 7, 2010
Curis: The Wall Street Analyst Forum Presentation Transcript
Thu, Sep 20, 2007

Curis Announces Presentation of CUDC-427 and Erivedge(R) Clinical Results at ASCO Annual Meeting

GlobeNewswire (Thu, 7:00AM)
Curis Announces Approval of Erivedge(R) in Australia

GlobeNewswire (May 10, 2013)
Curis Reports First Quarter 2013 Financial Results

GlobeNewswire (Apr 30, 2013)
Curis Announces Erivedge(R) Receives Positive CHMP Opinion for Conditional Approval in European Union

GlobeNewswire (Apr 26, 2013)
Curis to Present at the Needham 12th Annual Healthcare Conference

GlobeNewswire (Apr 24, 2013)
Curis to Release First Quarter 2013 Financial Results and Hold Conference Call on April 30, 2013

GlobeNewswire (Apr 23, 2013)
Curis to Present at the BioCentury Future Leaders in the Biotech Industry Conference

GlobeNewswire (Mar 29, 2013)
Curis Announces Appointment of Kenneth Pienta, M.D. to Board of Directors

GlobeNewswire (Mar 11, 2013)
Curis to Present at the Roth Capital Partners 25th Annual Growth Stock Conference

GlobeNewswire (Mar 11, 2013)
Curis to Present at the Cowen and Company 33rd Annual Health Care Conference

GlobeNewswire (Feb 25, 2013)
Curis Reports Fourth Quarter and Year-End 2012 Financial Results

GlobeNewswire (Feb 20, 2013)
Curis Appoints Ali Fattaey, Ph.D. as President and Chief Operating Officer

GlobeNewswire (Feb 19, 2013)
Curis to Present at Upcoming Investor Conferences

GlobeNewswire (Feb 15, 2013)
Curis to Release Fourth Quarter and Year End 2012 Financial Results and Hold Conference Call on February 20, 2013

GlobeNewswire (Feb 13, 2013)
Curis Announces Dosing of First Patient in Phase I Clinical Trial of Dual PI3 Kinase and HDAC Inhibitor CUDC-907

GlobeNewswire (Jan 24, 2013)
Curis Announces Closing of $30 Million Secured Debt Financing

GlobeNewswire (Dec 12, 2012)
Curis Announces U.S. Patent Issuance Covering HSP90 Inhibitor Debio 0932

GlobeNewswire (Dec 6, 2012)
Curis to Present at the Oppenheimer 23rd Annual Healthcare Conference

GlobeNewswire (Dec 6, 2012)
Curis Announces $30 Million Secured Debt Financing to Support Development of Proprietary Pipeline

GlobeNewswire (Nov 28, 2012)
Curis Announces Worldwide In-Licensing of IAP Inhibitor GDC-0917 From Genentech

GlobeNewswire (Nov 28, 2012)

CRIS vs. ETF Alternatives

Company Description

We are a drug discovery and development company that is committed to leveraging our innovative signaling pathway drug technologies in seeking to develop next generation targeted cancer therapies. Biological signaling pathways, also referred to as signaling pathways, are prominent regulators of... More

Sector: Healthcare

Industry: Biotechnology

Country: United States

BTM
Big move before earnings call in $CRIS. Hmm...
Feb 19, 4:05 PM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Crazysight
$CRIS well positioned, earnings Monday, sales of nd Erivedge a potential catalyst, then good chance of EMA/CHMP approval in 2 weeks!
Jan 31, 10:37 AM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

rpainter22
Top 10 Best-Rated Small Cap Stocks: WX, AZPN, CRIS, OPTR, SREV, AMRN, AXAS, KNOL, LOGM, ORB (Jan 09, 2012) http://bit.ly/x87VC6
1/9/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Chemistfrog
Loving oversold biotechs that haven't "caught back up" yet: CRMD, CTSO.OB, PPHM, BIOD, DCTH, CLSN, CRIS, LPTN and EXEL.
12/3/11
Reply (3)

• !Report Abuse
View all 3 replies
Chemistfrog: CC is Tues, I bought in case they have good news about licensing or resuming their program I'll sell on spike. If no news at CC dump it..
12/5/11
• !Report Abuse
Sakoku: nice spike
12/7/11
• !Report Abuse
Add a reply...

140 characters

Ryan Mallory
Watch-List Today http://bit.ly/oaCdj5 ADAT ACAD HCKT BORN TGE TNAV OMPI GIGM CRIS GNET CYBE -Great list, bud!
7/6/11
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

greenbackers
PEC explosion. LEDS worst% SHZ best pre mkt upping. CRIS of interest on gap filling under 3
1/13/11
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Justin M. Hall
Rx Investors' HSP-90 & Hedge Hog Pathways Index ==> INFI, MYRX, SNTA,CRIS ==> http://bit.ly/bxkxgm/
10/1/10
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

David White
ASCO conference starts at the end of this coming week. Some stocks to watch: CLDX, ARQL, BMY, CELG, CRIS, PVCT.OB.
5/29/10
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Drug Recruiter
GILD, NVS, SPPI, IMUC, LIXT, ACTC.OB, CYTX, CVM, DCTH, BOCX, AGEN, ACCP, CUR, CCEL.OB, CRIS, OPXA, CYTK, LGND, ISPH,
9/27/09
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

LATEST REPLIES

Chemistfrog
Loving oversold biotechs that haven't "caught back up" yet: CRMD, CTSO.OB, PPHM, BIOD, DCTH, CLSN, CRIS, LPTN and EXEL.
12/3/11
Reply (3)

• !Report Abuse
View all 3 replies
Chemistfrog: CC is Tues, I bought in case they have good news about licensing or resuming their program I'll sell on spike. If no news at CC dump it..
12/5/11
• !Report Abuse
Sakoku: nice spike
12/7/11
• !Report Abuse
Add a reply...

140 characters

CRIS Curis, Inc.

CRIS

Curis, Inc.